GlycoEra:
The New Treatment Dimension

Advancing Glycan-Mediated Therapy

GlycoEra has developed a game-changing glycoengineering platform to build a high-value pipeline of novel biologics to address unmet medical needs. GlycoEra’s CustomGlycan platform can overcome the limitations and complexities of controlling glycosylation through rational engineering of glycan structures and glycosylation sites on specific protein targets to unlock unique biological pathways. With its robust discovery engine, GlycoEra has generated novel assets to treat very challenging diseases.

Latest News

  • November 5, 2021

    GlycoEra AG raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform. View Press Release

  • September 3, 2021

    Veronica Gambillara Fonck, CEO of GlycoEra, will be presenting at the Swiss Biotech Day on 7 September 2021

  • January 5, 2021

    GlycoEra AG announces its incorporation with the purpose of leveraging a proprietary glycoengineering platform to develop a pipeline of novel biologics for inflammatory disease, autoimmune disorder and immuno-oncology indications. View press release

View more news